Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Sep 1;112(5):1646-54.
doi: 10.1182/blood-2008-01-130237. Epub 2008 May 23.

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Wendy Stock  1 , Mei La, Ben Sanford, Clara D Bloomfield, James W Vardiman, Paul Gaynon, Richard A Larson, James Nachman; Children's Cancer Group; Cancer and Leukemia Group B studies
Affiliations
Clinical Trial

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

Wendy Stock et al. Blood. .

Abstract

We performed a retrospective comparison of presenting features, planned treatment, complete remission (CR) rate, and outcome of 321 adolescents and young adults (AYAs) ages 16 to 20 years with newly diagnosed acute lymphoblastic leukemia (ALL) who were treated on consecutive trials in either the Children's Cancer Group (CCG) or the Cancer and Leukemia Group B (CALGB) from 1988 to 2001. CR rates were identical, 90% for both CALGB and CCG AYAs. CCG AYAs had a 63% event-free survival (EFS) and 67% overall survival (OS) at 7 years in contrast to the CALGB AYAs, in which 7-year EFS was only 34% (P < .001; relative hazard rate [RHR] = 2.2) and OS was 46% (P < .001; RHR = 1.9). While CALGB AYAs aged 16 to 17 years achieved similar outcomes to all CCG AYAs with a 7-year EFS of 55%, the EFS for 18- to 20-year-old CALGB patients was only 29%. Comparison of the regimens showed that CCG AYAs received earlier and more intensive central nervous system prophylaxis and higher cumulative doses of nonmyelosuppressive agents. There were no differences in outcomes of those who reached maintenance therapy on time compared with those who were delayed. Based on these observations, a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of EFS and OS. (A) Comparison of EFS among CALGB (gray line) and CCG (black line) patients. The 7-year RHR for CALGB patients was 2.2 (CI, 1.6-3.0; P < .001). (B) Comparison of OS among CALGB (gray line) and CCG (black line) patients. The 7-year relative hazard ratio (RHR) for death in CALGB patients was 1.9 (CI, 1.3-2.7; P < .001).
Figure 2
Figure 2
Estimated incidence of isolated CNS relapses. The 7-year estimated incidence of isolated CNS relapses (ICNS) of 11% for CALGB patients (9 events) was significantly higher than the ICNS rate of 1.4% (2 events) for CCG patients (P < .001); RIR, 9.2 (CI, 2.0-42.7).
Figure 3
Figure 3
Age effect on outcome. CALGB patients aged 16 to 17 years had a 7-year EFS of 55%, which was similar to a 64% EFS for 16- to 17-year-old CCG patients (P = .49). CALGB patients aged 18 to 20 years old had a 7-year EFS of 29%, which was significantly worse than that for the younger CALGB patients and the 57% EFS for 18- to 20-year-olds on CCG trials (P = .01; RHR, 2.1 [CI, 1.2-3.8]).
See this image and copyright information in PMC

Comment in

References

    1. Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2005;130:166–173. - PubMed
    1. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663–1671. - PubMed
    1. Mattano L, Stock W, Nachman JB. Adolescents/young adults with ALL: cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. In: Bleyer A, O'Leary M, Barr R, Ries LAG, editors. Bethesda, MD: National Cancer Institute; 2006. NIH Pub. No. 06–5767.
    1. Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12:463–473. - PubMed
    1. Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev. 2004;30:37–51. - PubMed

Publication types